Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health

{
  "signal_id": "7f3ae22e-df10-d9ea-d92d-b840e944a2b9",
  "signal_type": "news",
  "signal_subtype": "receives_award",
  "detected_at": "2026-09-30T12:30:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/30/3371858/0/en/novo-s-investigational-obesity-and-diabetes-drug-cagrisema-reduces-food-noise-and-shows-benefits-in-organ-and-bone-health-easd-2026.html",
    "award": "Best Abstract Award at EASD 2026",
    "event": "EASD 2026",
    "title": "Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026",
    "excerpt": "Bagsværd, Denmark, 30 September 2026 – Novo Nordisk today announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. In a 52-week functional magnetic resonance imaging (fMRI) study, a brain scan technique that shows how the brain responds to cues, in adults with overweight or obesity, CagriSema modified brain responses to high-calorie food cues in regions linked to cravings, reward, sensory processing and behavioural control. Additionally, CagriSema substantially improved eating behaviour, reduced ‘food noise’, cravings, hunger, appetite, and food-related thoughts and improved craving control after both 22 and 52 weeks of treatment. In the study, also awarded a Best Abstract Award at EASD 2026, the improvements were also associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, p<0.0001).¹ Overall, the results suggest CagriSema may help address biological drivers that make sustained weight management difficult, including hunger, cravings and food preoccupation, not just calorie intake. Separately, in a diabetes MRI sub-study, which evaluated whole body metabolic effects in the phase 3a REIMAGINE 1 trial in adults with early type 2 diabetes, CagriSema 2.4 mg/2.4 mg produced significant reductions in fat in the...",
    "product": "CagriSema",
    "summary": "Novo Nordisk's study on its drug CagriSema received a Best Abstract Award at the EASD 2026 conference.",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/f87e6f85-3e50-4571-b9e5-8f683431f855",
    "confidence": 0.8,
    "product_data": {
      "name": "CagriSema",
      "full_text": "investigational obesity and diabetes drug CagriSema",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical",
      "future_tech"
    ],
    "published_at": "2026-09-30T12:30:00Z",
    "article_sentence": "In the study, also awarded a Best Abstract Award at EASD 2026, the improvements were also associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, p<0.0001).¹",
    "related_company_name": "European Association for the Study of Diabetes",
    "related_company_domain": "easd.org"
  }
}

curl https://signals.autobound.ai/v1/signals/7f3ae22e-df10-d9ea-d92d-b840e944a2b9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'